Document Detail

A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: Development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs.
MedLine Citation:
PMID:  22213574     Owner:  NLM     Status:  Publisher    
ELND006 is a novel gamma secretase inhibitor previously under investigation for the oral treatment of Alzheimer's disease. ELND006 shows poor solubility and has moderate to high permeability, suggesting it is a Biopharmaceutics Classification System Class II compound. The poor absolute oral bioavailability of the compound in fasted dogs (F ∼11%) is attributed to poor aqueous solubility. In addition, inhibiting amyloid precursor protein but not Notch cleavage is an important goal for gamma secretase inhibitors; therefore, significant variation in bioavailability resulting from food consumption is a potential liability for this class of compounds. The objective of the present study was to determine if an ELND006 nanocrystalline formulation would offer improved and predictable pharmacokinetics. ELND006 was formulated as a nanosuspension with a mean particle size of less than 200 nm, which was stable in particle size and crystallinity for over 1 year. In addition, ELND006 nanosuspension exhibited rapid dissolution in comparison with reference active pharmaceutical ingredient (API). The in vivo performance of the ELND006 nanosuspension was tested in fed and fasted beagle dogs and compared with a gelatin capsule containing reference API. The results show that nanosizing ELND006 profoundly improved the oral bioavailability and virtually eliminated variation resulting from food intake. © 2011 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.
Kevin Quinn; Rampurna Prasad Gullapalli; Elaine Merisko-Liversidge; Erich Goldbach; Angelina Wong; Gary G Liversidge; Wherly Hoffman; John-Michael Sauer; John Bullock; George Tonn
Related Documents :
19486454 - Use of a magnetic attachment to retain an obturator prosthesis for an osseous defect.
23007094 - Climate change impacts on body size and food web structure on mountain ecosystems.
7490674 - The effect of the slope inclination of buccal polished surface of mandibular denture ba...
21983204 - Advertising influences on young children's food choices and parental influence.
15707054 - Tracking the sources of nitrate in groundwater using coupled nitrogen and boron isotope...
12741534 - Effect of frozen storage on physical properties of pasta filata and nonpasta filata moz...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-12-28
Journal Detail:
Title:  Journal of pharmaceutical sciences     Volume:  -     ISSN:  1520-6017     ISO Abbreviation:  -     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2012-1-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985195R     Medline TA:  J Pharm Sci     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 Wiley Periodicals, Inc.
Research and Development, Elan Pharmaceuticals, South San Francisco, California 94080.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  American College of Physicians Ethics Manual: sixth edition.
Next Document:  Are survivors of childhood cancer with an unfavourable psychosocial developmental trajectory more li...